"The Simcyp Simulator is well recognized for its applications in clinical development, including prediction of drug-drug interactions, drug-food interactions, and drug performance in populations such as pediatrics and organ impairment,” said
Simcyp Biopharmaceutics software also helps sponsors develop the evidence needed to attain biowaivers which are used in lieu of conducting clinical studies. It is available as a standalone product and is designed for life sciences companies of all sizes looking to optimize their therapies’ formulations to maximize safety, efficacy, and patient convenience.
Simcyp Biopharmaceutics software delivers value and unique capabilities across several areas that are critical to achieving formulation success, including:
- Replace Costly Clinical Bioequivalence Studies - With growing encouragement from regulators, virtual bioequivalence studies (VBE) leverages physiologically based pharmacokinetic (PBPK) modeling to demonstrate bioequivalence (BE) between test and reference drugs. Simcyp Biopharmaceutics software includes a VBE module that automates elements of trial design significantly enhancing opportunities for attaining biowaivers.
- Optimize Formulation for Complex Drugs: Biopharmaceutical Classification System (BCS) Class II-IV drugs are challenging to create oral formulations for because of their poor solubility and/or absorption. Simcyp Biopharmaceutics software facilitates developing these drugs, which constitute 90% of new drug candidates.
- Inform Drug Labels - Recent FDA guidance recognizes physiologically-based pharmacokinetic (PBPK) models as a valuable technology for identifying and optimizing the impact of gastrointestinal effects such as meal type and pH. Simcyp Biopharmaceutics software advances these capabilities for optimizing dosing strategies and providing label guidance to clinicians.
For more information about Simcyp Biopharmaceutics software, please visit our website.
About
Certara Contact:
sheila.rocchio@certara.com
Media Contact:
ariane.lovell@finnpartners.com
Investor Relations Contact:
ir@certara.com
Source:
2023 GlobeNewswire, Inc., source